1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Tauns Laboratories, Inc.

Tauns Laboratories, Inc.

TTSE:197A
499.00
JPY
-3.00
(-0.60%)
54.16BMarket Cap
Nov 12Next Earn
Tauns Laboratories, Inc.
TSE:197A
(Tokyo Stock Exchange)

Recent

price

499.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
JPY
174.57
156.73
184.35
183.09
- -
Revenue per Share
44.81
30.35
57.74
62.07
- -
Basic EPS, GAAP
83.95
-43.23
59.74
16.68
- -
Free Cash Flow per Basic Share
18
19
6
27.35
- -
Dividend per Share
73.56
84.9
136.67
169.12
163.58
Book Value per Share
32.19
45.8
99.46
131.86
127.96
Tangible Book Value per Share
100
100
100
102
103
Basic Weighted Avg Shares
17,457
15,673
18,435
18,628
- -
Sales/Revenue/Turnover
64.1
31.69
43.56
44.37
- -
Operating Margin (%)
567
640
676
715
- -
Depreciation Expense
4,481
3,035
5,774
6,315
- -
Net Income, GAAP
43.82
34.8
26.3
23
- -
Effective Tax Rate (%)
25.67
19.36
31.32
33.9
- -
Profit Margin (%)
3,099
2,939
6,441
5,947
5,759
Working Capital
2,968
2,236
4,307
8,809
12,868
LT Debt
7,356
8,490
13,667
17,418
17,406
Total Equity
- -
20.41
29.4
21.91
- -
Return on Invested Capital (%)
- -
22.41
30.38
23.23
- -
Return on Capital (%)
- -
38.3
52.12
40.63
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
ST Debt
9,283
LT Borrowings
12,868
LT Finance Leases
- -
Preferred Equity and Hybrid Capital
- -
Shares Outstanding
106
Market Capitalization
54,160

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Total Current Assets
18,908
Cash, Cash Equivalents & STI
4,255
Accounts Receivable, Net
7,207
Inventories
6,433
Total Current Liabilities
13,149
Payables & Accruals
- -
ST Debt
9,283
Deferred Revenue
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
27.45%
Free Cash Flow
- -
- -
-71.59%
Net Income, GAAP
- -
- -
9.38%
Sales/Revenue/Turnover
- -
- -
1.05%
Total Cash Common Dividend
- -
- -
363.74%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
2,063
18,435
2025
- -
- -
- -
- -
18,628
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
-1.32
57.74
2025
- -
- -
- -
- -
62.07
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
6
2025
- -
- -
- -
- -
27.35
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
TAUNS Laboratories, Inc. innovates and produces an array of *in vitro* diagnostic solutions and research reagents. The firm specializes in rapid diagnostic test kits for various infectious diseases, distributed to medical facilities worldwide, alongside handling industrial and medical measurement devices. Established in Izunokuni, Japan, in 1987, the company is actively pursuing new diagnostic technologies in areas such as cancer, microbiomes, and genomics through recent strategic collaborations.